Comprehensive epigenomic studies in multiple myeloma (MM) that unravel the connections between major epigenetic regulators, their intertwined collaboration and the potential of combinatorial targeting remain limited. Utilizing ChIP-seq, ATAC-seq, RNA-seq, and DNA methylation (DNAme) data, we generated whole-genome chromatin annotations from normal plasma cells and MM patients, revealing epigenomic re-configuration affecting downstream genes involved in tumour growth and survival. Primary MM samples showed global DNA hypomethylation but site-specific hypermethylation was observed at transcription start sites, promoters, and enhancers. Moreover, increased deposition of H3K27me3 was observed in clinically relevant functional chromatin clusters. Combined EZH2 and DNMTs inhibition resulted in extensive epigenomic alterations activating apoptosis and cell cycle genes, leading to increased G2/M arrest and apoptosis in MM cell lines. Our findings provide novel insights into the role of epigenetic gene silencing in MM tumorigenesis and the interplay between the Polycomb repressive complex 2 and DNAme. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1038/s41598-025-17093-z.
Combinatorial DNMTs and EZH2 inhibition reprograms the H3K27me3 and DNAme-mediated onco-epigenome to suppress multiple myeloma proliferation.
组合式 DNMTs 和 EZH2 抑制重编程 H3K27me3 和 DNAme 介导的致癌表观基因组,从而抑制多发性骨髓瘤增殖
阅读:7
作者:Atienza Párraga Alba, Nylund Patrick, Diamanti Klev, Garrido-Zabala Berta, Tziola Stefania Iliana, Vasquez Louella, Pyl Paul Theodor, Raykova Doroteya, Skaftason Aron, Ma Anqi, Jin Jian, MartÃn-Subero José Ignacio, Ãberg Fredrik, De Bruyne Elke, Komorowski Jan, Jernberg Wiklund Helena, Kalushkova Antonia
| 期刊: | Scientific Reports | 影响因子: | 3.900 |
| 时间: | 2025 | 起止号: | 2025 Aug 27; 15(1):31568 |
| doi: | 10.1038/s41598-025-17093-z | 靶点: | H3 |
| 研究方向: | 肿瘤 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
